Literature DB >> 1616857

Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line.

B Long1, B M McKibben, M Lynch, H W van den Berg.   

Abstract

We have examined the expression of receptors for epidermal growth factor (EGFR) by the ZR-75-1 human breast cancer cell line and tamoxifen resistant (ZR-75-9al 8 microM) and oestrogen independent/tamoxifen sensitive (ZR-PR-LT) variants. The parent line expressed a single class of high affinity binding sites (4,340 +/- 460 receptors/cell; Kd 0.23 +/- 0.04 nM). ZR-75-9al 8 microM cells, routinely maintained in medium containing 8 microM tamoxifen, were negative for oestrogen receptor (ER) and progesterone receptor (PGR) and expressed a markedly increased number of EGFR (14,723 +/- 2116 receptors/cell). Receptor affinity was unchanged. Time dependent reversal of the tamoxifen resistant phenotype was accompanied by a return to ER and PGR positivity and a fall in EGFR numbers to parent cell levels. In contrast ZR-PR-LT cells had a greatly reduced EGFR content (803 +/- 161 receptors/cell) accompanying elevated PGR numbers. Pre-treatment of these cells with suramin or mild acid stripping failed to expose receptors which may have been occupied by endogenously produced ligand. Increased proliferation of ZR-75-1 cells treated with EGFR (0.01-10 ng ml-1) was only observed in serum-free medium lacking insulin and oestradiol. Under these conditions untreated cells failed to proliferate. Both variant lines continued to proliferate in serum free medium in the absence or presence of insulin and oestradiol but failed to respond to exogenous EGF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616857      PMCID: PMC1977788          DOI: 10.1038/bjc.1992.182

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells.

Authors:  C Dati; S Antoniotti; D Taverna; I Perroteau; M De Bortoli
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

2.  T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.

Authors:  M L Graham; N L Krett; L A Miller; K K Leslie; D F Gordon; W M Wood; L L Wei; K B Horwitz
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

3.  The Woolf plot is more reliable than the Scatchard plot in analysing data from hormone receptor assays.

Authors:  D D Keightley; N A Cressie
Journal:  J Steroid Biochem       Date:  1980-11       Impact factor: 4.292

Review 4.  Growth regulation of human breast carcinoma occurs through regulated growth factor secretion.

Authors:  M E Lippman; R B Dickson; E P Gelmann; N Rosen; C Knabbe; S Bates; D Bronzert; K Huff; A Kasid
Journal:  J Cell Biochem       Date:  1987-09       Impact factor: 4.429

5.  Epidermal growth factor stimulation of human breast cancer cells in culture.

Authors:  C K Osborne; B Hamilton; G Titus; R B Livingston
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

6.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

7.  High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.

Authors:  H W van den Berg; J Martin; M Lynch
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

8.  Increased epidermal growth factor receptor gene expression by gamma-interferon in a human breast carcinoma cell line.

Authors:  A W Hamburger; G D Pinnamaneni
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

9.  Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture.

Authors:  D W Barnes
Journal:  J Cell Biol       Date:  1982-04       Impact factor: 10.539

10.  Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen.

Authors:  H W van den Berg; W J Leahey; M Lynch; R Clarke; J Nelson
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

View more
  12 in total

Review 1.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

2.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Authors:  Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 3.  EGF receptor in neoplasia and metastasis.

Authors:  K Khazaie; V Schirrmacher; R B Lichtner
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

4.  The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.

Authors:  J G Klijn; M P Look; H Portengen; J Alexieva-Figusch; W L van Putten; J A Foekens
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

5.  Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.

Authors:  Wei Yue; Ping Fan; Jiping Wang; Yuebai Li; Richard J Santen
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

6.  Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

Authors:  R I Nicholson; R A McClelland; J M Gee; D L Manning; P Cannon; J F Robertson; I O Ellis; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

Review 7.  Preclinical models for the evaluation of targeted therapies of metastatic disease.

Authors:  S A Eccles; G Box; W Court; J Sandle; C J Dean
Journal:  Cell Biophys       Date:  1994

8.  Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression.

Authors:  H W van den Berg; D Claffie; M Boylan; J McKillen; M Lynch; B McKibben
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

9.  Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer.

Authors:  H J van Slooten; B A Bonsing; A J Hiller; G T Colbern; J H van Dierendonck; C J Cornelisse; H S Smith
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

10.  Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.

Authors:  S Okubo; J Kurebayashi; T Otsuki; Y Yamamoto; K Tanaka; H Sonoo
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.